Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,648
Out of 5,043 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.46 | +1,612.33% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.04 | +390.20% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.38 | +236.13% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $33.18 | +153.16% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $7.49 | +434.05% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $8.99 | +22.36% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $6.20 | +238.71% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $7.05 | +12,665.96% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.46
Upside: +1,612.33%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.04
Upside: +390.20%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.38
Upside: +236.13%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $33.18
Upside: +153.16%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $7.49
Upside: +434.05%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $8.99
Upside: +22.36%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.20
Upside: +238.71%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $7.05
Upside: +12,665.96%